Login
Dad Says Autism ‘Miracle Drug’ Drastically and Immediately Improved His Son’s Severe Symptoms
Like most 4-and-a-half-year-olds, Lev Bielski loves playing with his big sister, spelling his favorite pastime “pool” on the letter board and cuddling with his parents on movie nights. But it’s been a long journey for the golden-haired “surfer bro” who loves splashing in the water at surf camp and trying on Dad’s volunteer firefighter gear. Up until four months ago, Lev was self-harming until he was black and blue, unable to make eye contact and keeping to himself in a corner all day.
He was inching dangerously close to being confined by a punishing helmet and sedated with heavy antipsychotic meds to mitigate his severe autism that left him incapable of functioning by himself. The outlook was bleak for the tormented tyke, who showed symptoms before he was a year old. His parents, Gabriella and Matthew Bielski, chased every therapeutic intervention and specialist across the country for years, to no avail. The family desperately needed a lifeline, as no medication is approved to address the core symptoms related to autism.
“Half my day was running a business and half was holding him down and trying to keep him from hurting himself — we had no solution,” Matthew Bielski told The Post.
That was until research led the anguished couple to Yamo Pharmaceuticals, a decade-old clinical-stage biopharmaceutical company dedicated to treating the core symptoms of autism spectrum disorder with its “miracle drug” called L1-79.
They managed to get Lev the therapy before FDA approval thanks to the FDA’s expanded-access program — and the results, they said, were immediate.
It’s the Best Time to Get a Flu Shot. The CDC Tool to Find Vaccines Near You Doesn’t Work
Planning to get your flu shot or a COVID-19 booster, but aren’t sure where to get vaccinated? There are many online resources to guide you. But a widely used, free federal search tool to help people find the nearest location offering vaccines isn’t working, just ahead of respiratory virus season.
Vaccines.gov, a website operated by the U.S. Centers for Disease Control and Prevention and the Department Health and Human Services, helps Americans locate and schedule nearby vaccines.
Simply enter your zip code, and vaccines.gov provides a list of the closest pharmacies and providers offering certain vaccinations, as well as their contact information.
The problem? The search tool doesn’t function.
Odds of Losing Your Nails, Hair Rise With GLP-1 Use
U.S. News & World Report reported:
You’re up to four times more prone to losing a nail after you start a GLP-1 medicine than before, a new study suggests. Risk for nail discoloration also rises when taking GLP-1s, according to a French study. The findings were presented Wednesday in Vienna at the annual meeting of the European Academy of Dermatology and Venereology.
“Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal,” study co-author Dr. Charles Taïeb noted in a meeting news release. He’s a clinical dermatologist at Necker University Hospital in Paris. A second study presented at the meeting found that people taking a GLP-1 were also more prone to hair loss and scalp issues.
In the first study, Taïeb and colleagues compared nail changes in 1,904 people with type 2 diabetes and/or obesity — 575 who were using a GLP-1 and 1,329 who had never used the drugs. Overall, 66% of GLP-1 users reported some kind of nail disorder, compared to 53% of non-users, the researchers said.
The odds for “nail detachment” quadrupled among GLP-1 users compared to non-users, and 46% of GLP-1 users reported nail discoloration compared to 17% of non-users.
Pfizer, Moderna Lose Bids to Escape Bayer US mRNA Patent Lawsuit
A federal judge in Delaware on Monday rejected Pfizer, BioNTech, and Moderna’s requests to dismiss patent lawsuits filed against them by Bayer’s Monsanto unit over the messenger RNA technology used in their COVID-19 vaccines. US Circuit Judge William Bryson, sitting at the court by designation, said that the vaccine makers failed to show at an early stage of the case that the patent at issue was invalid or not infringed by their shots
Spokespeople for the vaccine makers did not immediately respond to requests for comment on the decision. “We are pleased with the court’s decision and remain confident in our position that Bayer’s patented innovations were used without authorization,” Bayer said in a statement.
Bayer sued the companies in January for allegedly copying technology developed by Monsanto in the 1980s for strengthening mRNA in crops and using it to stabilize the genetic material in their vaccines The vaccine makers argued that their manufacturing processes worked differently than Bayer’s technology.
Skipping Sweets During Antibiotic Treatment May Help Protect the Gut Microbiome
A new study by researchers at City of Hope suggests eating less sugar could protect the microbiome during antibiotic treatment. The study followed patients with blood cancer undergoing an intensive treatment called allogeneic hematopoietic cell transplant, a population at particularly high risk for severe gut microbiome disruption and associated side effects.
Published in Nature, the findings connect to the idea of “food as medicine” during cancer care and the ways diet can help us prevent and recover from illness. The research could lead to new treatment strategies for cancer patients and potentially others taking antibiotics.
“Antibiotics disrupt the diversity of our gut bacteria, or microbiomes, which play an essential role in supporting our immune systems and overall health,” said co-senior author Marcel van den Brink, M.D., Ph.D., president of City of Hope Los Angeles and City of Hope chief physician executive.
GLP-1s in the Media: Dutch News Groups Fined Over Positive Coverage
Several of the largest news organisations in the Netherlands have been fined thousands of euros for what regulators said was the unlawful promotion of GLP-1 medications. Dutch healthcare regulator the Health and Youth Care Inspectorate (IGJ) issued fines to a range of newspapers, magazines, and television broadcasters regarding their coverage of the weight loss and diabetes drugs between 2023 and 2025.
One media group faced combined penalties of €132 000 (£113 000) for articles it published. Another faced fines totalling almost €100 000. One of the articles attracting the regulator’s ire was coverage of a GLP-1 study in US veterans published in Nature Medicine. A newspaper wrote that the research showed that “weight loss drugs such as Ozempic” had been “found to offer far more health benefits than previously known.”
Another sanctioned article—specifically on Ozempic (semaglutide) — featured the headline “Popular weight loss drug turns out to be a medicine with many talents,” and another had, “The latest anti-obesity drugs are more effective than ever.”
